ArticleCellular and molecular life sciences : CMLS2022
Saponin-based adjuvant-induced dendritic cell cross-presentation is dependent on PERK activation.
Article in Cellular and molecular life sciences : CMLS, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 21 citations in OpenAlex.
- Article
- A refined low-dose murine model ofmBio · 2025Article
- Matrix-M adjuvant triggers inflammasome activation and enables antigen cross-presentation through induction of lysosomal membrane permeabilization.NPJ vaccines · 2025Article
- Leaf Saponins ofPharmaceutics · 2025Review
- Saponin-based adjuvant uptake and induction of antigen cross-presentation by CD11b+ dendritic cells and macrophages.NPJ vaccines · 2025Article
- Traditional Chinese medicine as potential adjuvants for tumor vaccines: a review of types, mechanisms, and forms.Frontiers in immunology · 2025Review
- Intricate Crosstalk Between Food Allergens, Phages, Bacteria, and Eukaryotic Host Cells of the Gut-skin Axis.The Yale journal of biology and medicine · 2024Article
- Mitochondria-associated endoplasmic reticulum membrane (MAM): a dark horse for diabetic cardiomyopathy treatment.Cell death discovery · 2024Review
- Plant-based nanoparticles targeting malaria management.Frontiers in pharmacology · 2024Review
- Design and Evaluation of Synthetic Delivery Formulations for Peptide-Based Cancer Vaccines.BME frontiers · 2024Article
- The Matrix-M™ adjuvant: A critical component of vaccines for the 21Human vaccines & immunotherapeutics · 2023Review
- Saponin-based adjuvants enhance antigen cross-presentation in human CD11cJournal for immunotherapy of cancer · 2023Article
- Advances in dendritic cell targeting nano-delivery systems for induction of immune tolerance.Frontiers in bioengineering and biotechnology · 2023Review
- Development and Evaluation of a Novel Diammonium Glycyrrhizinate Phytosome for Nasal Vaccination.Pharmaceutics · 2022Article
- Vaccine adjuvants to engage the cross-presentation pathway.Frontiers in immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Saponin-based adjuvants (SBAs) are promising new adjuvants that stand out as they not only enforce CD4 + T cell-mediated immunity and antibody responses, but also induce an unprecedented level of antigen cross-presentation by dendritic cells (DC) and subsequent CD8 + T cell activation. We discovered that SBA's ability to boost cross-presentation depends on the induction of lipid bodies (LBs). Moreover, the MHCII
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.